98%
921
2 minutes
20
Introduction: Chronic thromboembolic pulmonary hypertension (CTEPH) is a long-term sequel to pulmonary embolism (PE) whose incidence varies according to different published studies. We have carried out this study to determine its incidence within 2 years after index pulmonary embolism and to study limitations to an early diagnosis.
Material And Methods: OSIRIS is a multicentre, longitudinal cohort study. Patients were followed for 3, 6, 12, and 24 months after pulmonary embolism using a structured three-step algorithm. A physician-centered questionnaire at least one positive response in a screening proceeded to the second step, transthoracic echocardiography. The third step consisted of ventilation/perfusion lung scintigraphy and right heart catheterisation. A transthoracic echocardiography was performed in patients without positive response in the screening questionnaire after 2 years. CTEPH diagnosis required haemodynamic confirmation by right heart catheterisation and mismatched perfusion defects on lung scintigraphy.
Results: A total of 1191 patients were enrolled in 18 Spanish hospitals. Cumulative CTEPH incidence after 2-years PE was: 2.49 % (95 % CI: 1.68-3.56) and the incidence rate of CTEPH was 1.1 cases per 1000 person-months (95 % CI: 0.725; 1.60). The CTEPH algorithm presented a lack of adherence of 29 %; patient and physician preferences posed barriers to the triage algorithm The screening questionnaire, in patients who completed the follow-up, shows a specificity of 91.3 % (89.0-93.2 %) and negative predictive value of 99.4 % (98.4-99.8 %)..
Conclusions: OSIRIS provides practiced clinical based data on the chronic thromboembolic pulmonary hypertension incidence and identified barriers to the implementation of a 3-step triage algorithm for its detection.
Clinical Trial Registration: clinicaltrials.gov identifier: NCT03134898.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.thromres.2023.05.005 | DOI Listing |
Eur J Radiol
September 2025
Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Rationale/objectives: Image-based vascular biomarkers may help expedite evaluation of chronic thromboembolic pulmonary hypertension (CTEPH), which remains difficult to diagnose despite available effective therapies. We sought to determine if vascular heterogeneity and central redistribution on chest CT differed between CTEPH, pulmonary arterial hypertension (PAH), and control groups.
Materials/methods: We retrospectively included 108 patients who underwent right heart catheterization and chest CT (2011-2018).
Open Heart
September 2025
Division of Pulmonary Circulation, Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan
Background: Balloon pulmonary angioplasty (BPA) improves haemodynamics in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH). Previous studies on BPA have set the treatment objective to achieve a mean pulmonary arterial pressure (mPAP) of <30 mm Hg. However, the clinical impact of mPAP after BPA remains unclear.
View Article and Find Full Text PDFBr J Radiol
September 2025
Division of Cardiovascular Medicine, University of Sheffield.
Objective: Characterisation of thrombus is important for guiding treatment in chronic thromboembolic pulmonary hypertension (CTEPH). This study presents a novel scoring system for visual assessment of CTEPH on CT pulmonary angiography (CTPA), incorporating both disease location and extent to determine the impact on survival outcomes.
Methods: Patients with CTEPH were identified retrospectively from the ASPIRE registry.
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but serious disease caused by persistent thromboembolic obstruction or narrowing of the pulmonary arteries. Its prevalence varies, and many cases remain undiagnosed, contributing to a substantial clinical burden. This study aimed to summarize all CTEPH cases diagnosed in Latvia in 2024, calculate the annual incidence, and present additional epidemiological data from Latvian pulmonary hypertension (PH) registry.
View Article and Find Full Text PDFJ Heart Lung Transplant
September 2025
Cardiothoracic intensive care unit; Hôpital Marie Lannelongue, 133 Avenue de la Résistance, 92350 Le Plessis Robinson, France; INSERM U999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, 133 Avenue de la Résistance, 92350 Le Plessis Robinson, France; Pari
Introduction: Antiphospholipid syndrome (APS) is a risk factor for chronic thromboembolic pulmonary hypertension, which is generally treated by pulmonary endarterectomy (PEA). Patients with high antiphospholipid antibody (aPL) titers may be at increased risk for post-operative thrombotic complications. The aim of this study was to investigate potential associations linking APS with high aPL titers to mortality and complications after PEA.
View Article and Find Full Text PDF